Eos Energy stock falls after Fuzzy Panda issues short report
PALO ALTO/MCLEAN - Guardant Health (NASDAQ:GH), a $9 billion precision oncology company whose stock has surged over 200% in the past year, and Zephyr AI announced a strategic partnership aimed at developing novel cancer biomarkers for drug development and targeted therapy selection.
The collaboration will combine Guardant’s molecular data with Zephyr AI’s analytics platform to identify biomarkers that could potentially improve cancer treatment outcomes, according to a press release statement from the companies.
The partnership will integrate with Guardant’s existing artificial intelligence capabilities, focusing on using multimodal molecular data to generate predictions of targeted cancer therapy responses that can be validated through real-world data.
"By combining our industry-leading molecular data with Zephyr AI’s advanced analytics platform, we’re taking another major step toward realizing the full potential of precision oncology," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health.
Allen Chao, CEO of Zephyr AI, added that the collaboration represents "the convergence of unmatched real-world data, leading-edge diagnostics and cutting-edge machine learning."
The companies stated that this partnership aims to accelerate research and development for biopharmaceutical partners by providing insights that support drug development and personalized oncology treatments.
Guardant Health specializes in blood and tissue tests for cancer detection and monitoring, while Zephyr AI focuses on using artificial intelligence for precision medicine and drug development.
In other recent news, Guardant Health, Inc. announced that the U.S. Food and Drug Administration has approved its Guardant360 CDx blood test as a companion diagnostic for identifying advanced breast cancer patients with specific ESR1 mutations. This approval is significant as it allows the test to identify patients eligible for Eli Lilly’s Inluriyo, a treatment for certain types of advanced or metastatic breast cancer. Furthermore, several analyst firms have provided updates on Guardant Health following its recent Investor Day. Bernstein SocGen Group reiterated an Outperform rating with a $60 price target, while JPMorgan maintained an Overweight rating after the company’s analyst day, where Guardant Health updated its 2028 revenue projections to approximately $2.2 billion. Guggenheim raised its price target for the company to $67, citing new product launches. Additionally, TD Cowen increased its price target to $72, maintaining a Buy rating, despite a slight drop in the company’s shares amid broader sector weakness. These developments reflect ongoing interest and confidence in Guardant Health’s future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.